drugset / Trial / NCT04408586

Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker

NCT04408586

Phase 4 Completed 80 enrolled Mayo Clinic
RandomizedParallel-groupDouble-blindTreatment

Summary

Researchers are assessing the effects of weight loss medication vs a placebo among participants provided with a wearable activity tracker, digital wellness devices and lifestyle recommendations.

Timeline

Start
2020-06-03
Primary completion
2022-06-13
Completion
2022-10-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Phentermine Small molecule 7.5 mg
Comparator Topiramate Small molecule 46 mg

Indications